Serum MMP-9 as a Marker for Detection and Treatment Response Evaluation in Patients with Esophageal Squamous Cell Carcinoma

血清MMP-9可以作為食道鱗狀細胞癌病患診斷及治療評估的指標

張維倫(Wei-Lun Chang) ； 林逢嘉(Forn-Chia Lin) ； 顏家瑞(Chia-Jui Yen) ； 賴吾為(Wu-Wei Lai) ； 楊曉白(Hsiao-Bai Yang) ； 許博翔(Bor-Shyang Sheu)

《臺灣消化醫學雜誌》 28卷4期 (2011/12) Pp. 339-349

https://doi.org/10.6557/GJT.201112_28(4).0003

摘要

Background: Matrix　metalloproteinases (MMPs) play important roles in tumor development and progression. We tested whether the serum levels of MMP-3, 7 and 9 can serve as biomarkers to screen for esophageal squamous cell carcinoma (ESCC) or to evaluate its treatment response.Methods: Serum levels of MMP-3, 7 and 9 were measured in 63 ESCC patients and 30 healthy controls by enzyme-linked immunosorbent assay and correlated with the clinicopathological parameters. Patients who received neoadjuvant concurrent chemoradiation therapy (CCRT) were scheduled for serum follow-up and tumor treatment response evaluation.Results: ESCC patients had a higher level of serum MMP-9 than controls (median: 389 ng/mL vs. 251 ng/mL, P＜0.001), but not serum MMP-3 and 7. The area under ROC curve for serum MMP-9 to detect the presence of ESCC was 0.726 (95% CI: 0.616-0.837; P＜0.001). A positive correlation was noted between the serum level of MMP-9 and the tumor size of ESCC (Spearman’s ρ=0.392, P=0.001). Among 22 patients completed the CCRT, the serum level of MMP-9 were decreased after CCRT (P=0.017). Among 22 cases completed the follow-up, the patients with good CCRT response had a marginally lower level of serum MMP-9 after CCRT than those with poor response (median: 174.7 ng/mL vs. 225.9 ng/mL, P=0.203).Conclusion: Serum MMP-9 levels are elevated in ESCC patients, and correlate with tumor size. The serial MMP-9 levels may be helpful to evaluate the response of CCRT for ESCC patients.

關鍵字

血清MMP-9 ； 食道鱗狀細胞癌 ； 腫瘤指標

並列摘要

Background: Matrix　metalloproteinases (MMPs) play important roles in tumor development and progression. We tested whether the serum levels of MMP-3, 7 and 9 can serve as biomarkers to screen for esophageal squamous cell carcinoma (ESCC) or to evaluate its treatment response.Methods: Serum levels of MMP-3, 7 and 9 were measured in 63 ESCC patients and 30 healthy controls by enzyme-linked immunosorbent assay and correlated with the clinicopathological parameters. Patients who received neoadjuvant concurrent chemoradiation therapy (CCRT) were scheduled for serum follow-up and tumor treatment response evaluation.Results: ESCC patients had a higher level of serum MMP-9 than controls (median: 389 ng/mL vs. 251 ng/mL, P＜0.001), but not serum MMP-3 and 7. The area under ROC curve for serum MMP-9 to detect the presence of ESCC was 0.726 (95% CI: 0.616-0.837; P＜0.001). A positive correlation was noted between the serum level of MMP-9 and the tumor size of ESCC (Spearman’s ρ=0.392, P=0.001). Among 22 patients completed the CCRT, the serum level of MMP-9 were decreased after CCRT (P=0.017). Among 22 cases completed the follow-up, the patients with good CCRT response had a marginally lower level of serum MMP-9 after CCRT than those with poor response (median: 174.7 ng/mL vs. 225.9 ng/mL, P=0.203).Conclusion: Serum MMP-9 levels are elevated in ESCC patients, and correlate with tumor size. The serial MMP-9 levels may be helpful to evaluate the response of CCRT for ESCC patients.

並列關鍵字

serum MMP-9 ； esophageal squamous cell carcinoma ； tumor marker